Get the Stockscreener App
128.37
0.03%
0.04
Pre-market:
128.85
0.48
+0.37%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $128.37, with a volume of 7.05M.
It is up +0.03% in the last 24 hours and up +1.25% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$128.33
Open:
$130.96
24h Volume:
7.05M
Relative Volume:
0.72
Market Cap:
$317.05B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
36.13
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
-1.09%
1M Performance:
+1.25%
6M Performance:
+5.28%
1Y Performance:
+61.59%
1-Day Range:
$127.80
$131.08
1-Week Range:
$126.22
$131.47
52-Week Range:
$77.58
$135.05
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
128.37 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,191.94 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
ABBV
Abbvie Inc
|
243.87 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
154.21 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
161.07 | 263.09B | 60.48B | 10.40B | 8.05B | 3.3297 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Barclays Adjusts Merck & Co. Price Target to $150 From $140, Maintains Overweight Rating - marketscreener.com
Prediction: This Dividend ETF Will Thrive After 20 Years No Matter What the Market Does - The Motley Fool
Merck stock holds as 27 July 2026 article is built on filings and market context - Ad-hoc-news.de
Merck stock holds firm as oncology revenue supports valuation - Ad-hoc-news.de
Merck stock trades steadily as oncology revenue supports earnings outlook - Ad-hoc-news.de
Merck stock edges higher as Keytruda drives solid revenue growth - AD HOC NEWS
Merck & Co. stock holds after recent earnings and pipeline data - AD HOC NEWS
Merck & Co. Launches Early Access Program for Alimatravir - GuruFocus
Merck stock trades steadily as recent Keytruda momentum and solid oncology revenue frame valuation - AD HOC NEWS
Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries - CNBC TV18
Merck & Co., Inc. Revenue Breakdown – VIE:MRK - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Merck licenses experimental HIV pill to generic makers in 129 countries - Reuters
Merck signs licensing deals with companies including Viatris for new HIV pill - Seeking Alpha
Merck stock steadies as Keytruda drives Q1 2026 revenue growth - AD HOC NEWS
Merck stock holds recent gains as oncology and vaccines drive higher 2025 guidance - AD HOC NEWS
Merck's Once-Monthly HIV Prevention Pill Could Reach 129 Countries if Approved - Stock Titan
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development - Business Wire
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck stock trades steadily as Keytruda revenue supports earnings - Ad-hoc-news.de
Merck stock trades steadily as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds support after recent earnings and guidance - Ad-hoc-news.de
Return on assets % of Merck & Co., Inc. – BCS:MRK1 - TradingView
Operating margin % of Merck & Co., Inc. – BCS:MRKCL0 - TradingView
Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRK1 - TradingView
Net debt of Merck & Co., Inc. – BCS:MRK1 - TradingView
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
Non-controlling/minority interest of Merck & Co., Inc. – BCS:MRK0 - TradingView
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Commerzbank Aktiengesellschaft FI Decreases Stake in Merck & Co., Inc. $MRK - InsuranceNewsNet
Merck stock trades steadily as Keytruda and vaccine revenue underpin earnings - Ad-hoc-news.de
Merck stock trades steady as oncology and vaccines drive revenue growth - Ad-hoc-news.de
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $2,270,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Merck stock trades steadily as Keytruda growth underpins guidance - Ad-hoc-news.de
Merck & Co., Inc. (MRK) Stock Analysis: Navigating a 5.13% Upside Potential Amid Robust Growth - DirectorsTalk Interviews
Merck stock trades steady as oncology and vaccines drive growth - Ad-hoc-news.de
Merck stock holds firm as Keytruda drives revenue growth and late stage pipeline advances - ad-hoc-news.de
Merck stock holds steady as Keytruda drives revenue growth and investors watch oncology momentum - ad-hoc-news.de
Is Merck's Recent Restructuring a Confident Pivot or a Defensive Maneuver - Kavout | AI
Merck stock trades steady as Keytruda growth supports earnings outlook - ad-hoc-news.de
Merck stock trades steady as Keytruda growth underpins recent earnings - ad-hoc-news.de
Merck stock trades firm as Keytruda growth supports guidance - ad-hoc-news.de
Merck stock steadies as Keytruda drives double digit growth - ad-hoc-news.de
ETFs Investing in Merck & Co., Inc. Stocks - TradingView
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK) - Seeking Alpha
Merck stock trades near record territory as oncology and vaccines drive revenue growth - ad-hoc-news.de
MRK Stock Climbs As New Drugs And Targets Fuel Bull Case - StocksToTrade
New Cholesterol Pill, Earnings Growth Boost Merck Shares - FXEmpire
Merck stock edges higher as Keytruda drives double digit growth - ad-hoc-news.de
DUPONT CAPITAL MANAGEMENT Corp's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Maraldo David R. | EVP & Pres. MMD |
May 02 '26 |
Option Exercise |
112.16 |
552 |
61,912 |
18,371 |
| Guindo Chirfi | EVP, Access, Policy & Comms |
Apr 29 '26 |
Option Exercise |
110.03 |
1,967 |
216,429 |
62,582 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD |
Apr 29 '26 |
Option Exercise |
110.03 |
2,597 |
285,748 |
16,477 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Apr 29 '26 |
Option Exercise |
110.03 |
2,518 |
277,056 |
162,778 |
| Williams David Michael | EVP,Chief Info&Digital Officer |
Apr 29 '26 |
Option Exercise |
110.03 |
1,377 |
151,511 |
32,395 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 29 '26 |
Option Exercise |
110.03 |
944 |
103,868 |
9,156 |
| Smart Dalton E. III | SVP Fin. - Global Controller |
Apr 30 '26 |
Option Exercise |
110.95 |
464 |
51,481 |
9,296 |
| Li Dean Y | Executive VP & President, MRL |
Apr 29 '26 |
Option Exercise |
110.03 |
4,722 |
519,562 |
96,757 |
| Zachary Jennifer | EVP, General Counsel |
Apr 29 '26 |
Option Exercise |
110.03 |
2,951 |
324,699 |
72,351 |
| Larson Betty D | EVP, Chief HR Officer |
Apr 30 '26 |
Option Exercise |
110.95 |
11,350 |
1,259,282 |
18,917 |
0.15%
3.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):